Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-037029

Chief Financial Officer sold 610 shares at $2.64 ($1,610)

  • Chief Financial Officer acquired 2,291 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Delfini Lisa · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-06-12 Exercise or conversion : show line 1 in the form 10b5-1 +2,291 $0.51 $1,171 30,209 D
2023-06-12 Sale : show line 2 in the form 10b5-1 −610 $2.64 $1,610 29,599 D
Open-market sales · 610 sh · avg $2.64 · $1,610

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-06-12 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −2,291 73,335 D
Loading xslF345X04/doc4.xml…